ABSENCE OF ANTIIDIOTYPIC ANTIBODIES IN IVIG PREPARATIONS TO AUTOANTIBODIES OF RARE AUTOIMMUNE-DISEASES

被引:12
作者
KRAUSE, I [1 ]
HACHAM, S [1 ]
GILBURD, B [1 ]
DAMIANOVITCH, M [1 ]
BLANK, M [1 ]
SHOENFELD, Y [1 ]
机构
[1] TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL
来源
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY | 1995年 / 77卷 / 03期
关键词
D O I
10.1006/clin.1995.1148
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Intravenous immunoglobulins (IVIG) were found to contain anti-idiotypic antibodies against autoantibodies of various autoimmune diseases. We examined commercial IVIG preparations, from three different manufacturers, for the presence of autoantibodies and anti-idiotypic antibodies of two rare autoimmune diseases-primary biliary cirrhosis [anti-pyruvate dehydrogenase (PDH) antibodies] and Goodpasture's syndrome (anti-NC1 antibodies). We used ELISA studies as well as immunoblotting and anti-PDH enzyme activity for the detection of anti-PDH antibodies. ELISA and immunofluorescence studies were used for the detection of anti-NC1 antibodies. The presence of antiidiotypic activity against anti-PDH antibodies was evaluated using inhibition ELISA studies, employing affinity-purified F(ab)(2)-anti-PDH fragments on Sepharose-bound IVIG [F(ab)(2)]. Anti-anti-NC1 activity was evaluated employing inhibition ELISA and immunofluorescence studies. The commercial IVIG preparations that were examined did not contain anti-PDH or anti-NC1 antibodies nor anti-idiotypic activity against these autoantibodies. We conclude that commercial IVIG may lack anti-idiotypic activity against rare autoantibodies. (C) 1995 Academic Press, Inc.
引用
收藏
页码:229 / 235
页数:7
相关论文
共 43 条
  • [1] ANTI-CYTOKINE NATURE OF NATURAL HUMAN-IMMUNOGLOBULIN - ONE POSSIBLE MECHANISM OF THE CLINICAL EFFECT OF INTRAVENOUS IMMUNOGLOBULIN THERAPY
    ABE, Y
    HORIUCHI, A
    MIYAKE, M
    KIMURA, S
    [J]. IMMUNOLOGICAL REVIEWS, 1994, 139 : 5 - 19
  • [2] INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF EXPERIMENTAL T-CELL-MEDIATED AUTOIMMUNE-DISEASE - UP-REGULATION OF T-CELL PROLIFERATION AND DOWN-REGULATION OF TUMOR-NECROSIS-FACTOR-ALPHA SECRETION
    ACHIRON, A
    MARGALIT, R
    HERSHKOVIZ, R
    MARKOVITS, D
    RESHEF, T
    MELAMED, E
    COHEN, IR
    LIDER, O
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (02) : 600 - 605
  • [3] AKASHI K, 1990, J RHEUMATOL, V17, P375
  • [4] POOLED HUMAN-IGG MODULATES CYTOKINE PRODUCTION IN LYMPHOCYTES AND MONOCYTES
    ANDERSSON, U
    BJORK, L
    SKANSENSAPHIR, U
    ANDERSSON, J
    [J]. IMMUNOLOGICAL REVIEWS, 1994, 139 : 21 - 42
  • [5] HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN TREATMENT IN GRAVES OPHTHALMOPATHY
    ANTONELLI, A
    SARACINO, A
    ALBERTI, B
    CANAPICCHI, R
    CARTEI, F
    LEPRI, A
    LADDAGA, M
    BASCHIERI, L
    [J]. ACTA ENDOCRINOLOGICA, 1992, 126 (01): : 13 - 23
  • [6] EFFECTS OF REPEATED DOSES OF INTRAVENOUS IMMUNOGLOBULIN IN MYASTHENIA-GRAVIS
    ARSURA, EL
    BICK, A
    BRUNNER, NG
    GROB, D
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1988, 295 (05) : 438 - 443
  • [7] UVEITIS AFTER ANTINEUTROPHIL CYTOPLASMIC ANTIBODY CONTAMINATION OF IMMUNOGLOBULIN REPLACEMENT THERAPY
    AYLIFFE, W
    HAENEY, M
    ROBERTS, SC
    LAVIN, M
    [J]. LANCET, 1992, 339 (8792) : 558 - 559
  • [8] THE EFFECT OF INTRAVENOUS GAMMA-GLOBULIN ON THE INDUCTION OF EXPERIMENTAL ANTIPHOSPHOLIPID SYNDROME
    BAKIMER, R
    GUILBURD, B
    ZURGIL, N
    SHOENFELD, Y
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1993, 69 (01): : 97 - 102
  • [9] BERCHTOLD P, 1989, BLOOD, V74, P2414
  • [10] BERKMAN SA, 1988, SEMIN HEMATOL, V25, P140